Skip to main content

Table 1 Performance of the CD8xPD-L1 signature, its components, and manual PD-L1 scoring in durvalumab-treated patients

From: Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Measure

Group (n)

Prevalence

PPV

(95% CI)

Median OS, months

(95% CI)

OS p-value

Median PFS, months

(95% CI)

PFS p-value

Training Set (n = 84)

 CD8xPD-L1

positive (26)

0.31

0.42 (0.23–0.63)

18.9 (8.2–NR)

0.024

5.3 (2.6–9.3)

0.00042

negative (58)

0.69

0.09 (0.03–0.19)

8.9 (4.1–12.9)

1.4 (1.2–1.4)

 CD8+ cell density

high (32)

0.38

0.34 (0.19–0.53)

18.9 (12.9–NR)

0.012

4.4 (1.4–7.6)

0.00045

low (52)

0.62

0.10 (0.03–0.21)

8.8 (4.3–11.1)

1.4 (1.2–2.3)

 PD-L1+ cell density

high (26)

0.31

0.39 (0.20–0.59)

18.9 (5.6–NR)

0.071

4.7 (1.6–7.6)

0.023

low (58)

0.69

0.10 (0.04–0.21)

8.9 (4.1–13.1)

1.4 (1.3–1.7)

 PD-L1 TC

≥25% (49)

0.58

0.29 (0.17–0.43)

17.9 (8.9–NR)

0.018

2.8 (1.4–5.3)

0.0048

< 25% (35)

0.42

0.06 (0.01–0.19)

7.6 (3.4–12.9)

1.4 (1.2–1.4)

Test Set (n = 79)

 CD8xPD-L1

positive (33)

0.42

0.36 (0.20–0.55)

24.2 (14.5–NR)

0.00011

7.3 (3.1–9.8)

0.00095

negative (46)

0.58

0.07 (0.01–0.18)

6.5 (4.2–9.8)

2.6 (1.4–3.9)

 CD8+ cell density

high (42)

0.53

0.24 (0.12–0.40)

20.3 (14.0–27.8)

0.0044

5.5 (3.1–9.2)

0.0054

low (37)

0.47

0.14 (0.05–0.29)

6.5 (3.6–9.8)

2.5 (1.4–4.1)

 PD-L1+ cell density

high (29)

0.37

0.38 (0.21–0.58)

24.3 (6.5–NR)

0.045

7.3 (2.6–9.2)

0.087

low (50)

0.63

0.08 (0.02–0.19)

9.3 (6.0–15.5)

2.8 (1.7–5.2)

 PD-L1 TC

≥25% (47)

0.59

0.28 (0.16–0.43)

15.5 (7.7–24.2)

0.19

4.8 (2.6–7.3)

0.25

< 25% (32)

0.41

0.06 (0.01–0.21)

7.8 (5.7–15.5)

2.8 (1.4–6.5)

  1. Abbreviations: CD8 Cluster of differentiation 8, CI Confidence interval, NR Not reached, OS Overall survival, PD-L1 Programmed death ligand-1, PFS Progression-free survival, PPV Positive predictive value, TC Tumor cell